Cargando…
β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2
The inhibitors for EGF receptor tyrosine kinase (EGFR-TKIs) such as gefitinib have been used as a standard treatment for non-small cell lung cancer (NSCLC), but the increasingly occurrence of drug resistance, the associated adverse effects and the enrichment of cancer stem cells significantly impede...
Autores principales: | Cheng, Haibo, Ge, Xiaoyin, Zhuo, Shiqin, Gao, Yanan, Zhu, Bo, Zhang, Junfeng, Shang, Wenbin, Xu, Dakang, Ge, Weihong, Shi, Liyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284059/ https://www.ncbi.nlm.nih.gov/pubmed/30555330 http://dx.doi.org/10.3389/fphar.2018.01413 |
Ejemplares similares
-
FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer
por: Li, Jian, et al.
Publicado: (2022) -
Dissolvable hyaluronic acid microneedles loaded with β-Elemene for the treatment of psoriasis
por: Wang, Chun, et al.
Publicado: (2022) -
β-Elemene: Mechanistic Studies on Cancer Cell Interaction and Its Chemosensitization Effect
por: Jiang, Ziyu, et al.
Publicado: (2017) -
Comparative Proteomics Analysis Reveals the Reversal Effect of Cryptotanshinone on Gefitinib-Resistant Cells in Epidermal Growth Factor Receptor-Mutant Lung Cancer
por: Cai, Peiheng, et al.
Publicado: (2022) -
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)